<?xml version="1.0" encoding="UTF-8"?>
<feed xmlns="http://www.w3.org/2005/Atom" xmlns:dc="http://purl.org/dc/elements/1.1/">
  <title>ScholarWorks Community:</title>
  <link rel="alternate" href="https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/425" />
  <subtitle />
  <id>https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/425</id>
  <updated>2026-07-04T11:38:34Z</updated>
  <dc:date>2026-07-04T11:38:34Z</dc:date>
  <entry>
    <title>Rapid Spontaneous Tumor Regression Mimicking Pseudoprogression in Pembrolizumab-treated Non–small Cell Lung Cancer</title>
    <link rel="alternate" href="https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/217703" />
    <author>
      <name>Yoo, Seung-Jin</name>
    </author>
    <author>
      <name>Lee, Hyun</name>
    </author>
    <author>
      <name>Myung, Jae Kyung</name>
    </author>
    <author>
      <name>Choi, Yun Young</name>
    </author>
    <author>
      <name>Lee, Soo Jin</name>
    </author>
    <id>https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/217703</id>
    <updated>2026-06-29T05:00:39Z</updated>
    <published>2026-05-01T00:00:00Z</published>
    <summary type="text">Title: Rapid Spontaneous Tumor Regression Mimicking Pseudoprogression in Pembrolizumab-treated Non–small Cell Lung Cancer
Authors: Yoo, Seung-Jin; Lee, Hyun; Myung, Jae Kyung; Choi, Yun Young; Lee, Soo Jin
Abstract: Atypical tumor responses can occur during immune checkpoint inhibitor therapy. A 71-year-old man receiving pembrolizumab treatment for stage IV non–small cell lung cancer was found on 18F-FDG PET/CT to have developed new lesions in the stomach, left adrenal gland, and lungs. Because a gastric biopsy confirmed metastatic disease, treatment was discontinued. Remarkably, all lesions resolved after 4 weeks without any treatment. Pembrolizumab therapy was restarted, and follow-up CT showed further reduction in the lung cancer without new lesions. This case of spontaneous regression of gastric metastasis mimicking a pseudoprogression response to pembrolizumab treatment highlights the possibility of unusual presentations during immunotherapy.</summary>
    <dc:date>2026-05-01T00:00:00Z</dc:date>
  </entry>
  <entry>
    <title>Atypical Symptoms on Admission Predict Progression to Heart Failure in Patients with First-Time Myocardial Infarction: Using Data from the Korean Multicenter Cohort Registry</title>
    <link rel="alternate" href="https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/210448" />
    <author>
      <name>Hwang, Seon Young</name>
    </author>
    <author>
      <name>Um, In Ae</name>
    </author>
    <author>
      <name>Kim, Sun Hwa</name>
    </author>
    <author>
      <name>Kim, Jiyoung</name>
    </author>
    <author>
      <name>Jeong, Myung Ho</name>
    </author>
    <id>https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/210448</id>
    <updated>2026-01-23T02:30:25Z</updated>
    <published>2026-01-01T00:00:00Z</published>
    <summary type="text">Title: Atypical Symptoms on Admission Predict Progression to Heart Failure in Patients with First-Time Myocardial Infarction: Using Data from the Korean Multicenter Cohort Registry
Authors: Hwang, Seon Young; Um, In Ae; Kim, Sun Hwa; Kim, Jiyoung; Jeong, Myung Ho
Abstract: Background: Identifying the initial factors predicting heart failure (HF) progression in patients with myocardial infarction (MI), a major cause of HF, is essential.
Objectives: We aimed to examine predictors of rehospitalization due to HF in patients with first-time MI from the Korea Acute Myocardial Infarction Registry-National Institutes of Health (KAMIR-NIH) prospective cohort between 2011 and 2015.
Methods: A secondary data analysis was conducted on a population of 8888 patients who completed 3 years of follow-up and had no history of MI, HF, or death. The HF group was defined as patients rehospitalized with an HF diagnosis due to worsening symptoms. A 1:4 propensity score matching analysis was performed on 11 baseline characteristics, and the clinical conditions and complications of the HF group (n = 252) were compared with the non-HF group (n = 991). Statistical analyses were performed using SAS version 9.4 and R version 4.2.3.
Results: A Cox proportional hazards model showed that the factors predicting rehospitalization due to HF were dyspnea (HR, 1.54; 95% CI, 1.16–2.04; P = .003), left ventricular ejection fraction &amp;lt;50% (HR, 2.71; 95% CI, 2.06–3.58; P &amp;lt; .001), and new-onset HF confirmed during hospitalization (HR, 1.77; 95% CI, 1.18–2.66; P = .006). Atypical chest pain (no chest pain) was significant only in univariate analysis.
Conclusions: This study highlights the importance of carefully monitoring symptoms and conditions during outpatient follow-up in post-MI patients, regardless of age, sex, or medical history. In particular, those who present with dyspnea at admission or develop new-onset HF during hospitalization should be considered high-risk for HF rehospitalization.</summary>
    <dc:date>2026-01-01T00:00:00Z</dc:date>
  </entry>
  <entry>
    <title>18F-FDG PET/CT imaging biomarkers for predicting atherosclerotic cardiovascular risk</title>
    <link rel="alternate" href="https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/216890" />
    <author>
      <name>이수진</name>
    </author>
    <id>https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/216890</id>
    <updated>2026-07-02T15:09:31Z</updated>
    <published>2025-11-14T00:00:00Z</published>
    <summary type="text">Title: 18F-FDG PET/CT imaging biomarkers for predicting atherosclerotic cardiovascular risk
Authors: 이수진</summary>
    <dc:date>2025-11-14T00:00:00Z</dc:date>
  </entry>
  <entry>
    <title>Neutrophil-to-Lymphocyte Ratio, Bone Marrow, and Visceral Fat Metabolism as Predictors of Future Cardiovascular Disease in an Asymptomatic Healthy Population</title>
    <link rel="alternate" href="https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/209080" />
    <author>
      <name>Lee, Soo Jin</name>
    </author>
    <author>
      <name>Kim, Jahae</name>
    </author>
    <author>
      <name>Kim, Ji Young</name>
    </author>
    <author>
      <name>Paeng, Jin Chul</name>
    </author>
    <author>
      <name>Choi, Yun Young</name>
    </author>
    <author>
      <name>Kim, Young Seo</name>
    </author>
    <author>
      <name>Choi, Kang-Ho</name>
    </author>
    <author>
      <name>Kim, Jeong-Min</name>
    </author>
    <author>
      <name>Choi, Nayeon</name>
    </author>
    <author>
      <name>Kim, Jiyeong</name>
    </author>
    <id>https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/209080</id>
    <updated>2026-02-01T12:37:03Z</updated>
    <published>2025-09-01T00:00:00Z</published>
    <summary type="text">Title: Neutrophil-to-Lymphocyte Ratio, Bone Marrow, and Visceral Fat Metabolism as Predictors of Future Cardiovascular Disease in an Asymptomatic Healthy Population
Authors: Lee, Soo Jin; Kim, Jahae; Kim, Ji Young; Paeng, Jin Chul; Choi, Yun Young; Kim, Young Seo; Choi, Kang-Ho; Kim, Jeong-Min; Choi, Nayeon; Kim, Jiyeong
Abstract: Background/Objectives: The neutrophil-to-lymphocyte ratio (NLR), a marker of systemic inflammation, is a known predictor of cardiovascular disease and overall mortality. We examined the relationship between the NLR and the metabolic activity of hematopoietic organs and visceral fat, and their association with the risk of atherosclerotic cardiovascular disease (ASCVD) in an asymptomatic healthy population. Methods: We retrospectively analyzed individuals who underwent F-18-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) as part of their health check-ups. Metabolic activity was quantified using standardized uptake values (SUVs) from the lumbar vertebral bone marrow, spleen, visceral, and subcutaneous fat, normalized to target-to-background ratios (TBRs) using the superior vena cava. NLR was calculated from absolute neutrophil and lymphocyte counts. Correlations between NLR, clinical parameters, organ TBRs, and ASCAD risk were analyzed. Results: Among 303 participants from three hospitals, the median NLR was 1.5 (range: 0.5–5.55). NLR showed weak correlation with the TBRs of bone marrow, visceral fat, and subcutaneous fat, as well as high-density lipoprotein cholesterol and body mass index (BMI). In logistic regression analysis adjusted for age and sex, BMI and the TBRs of bone marrow and visceral fat were independent predictors of elevated NLR (≥ 1.5). When integrating these parameters, NLR demonstrated strong predictive performance for identifying a high ASCVD risk (≥20% over 10 years), with an area under the curve of 0.826. Conclusions: In an asymptomatic healthy population, NLR is associated with FDG metabolic parameters of hematopoietic organs and adipose tissue. These combined measures may serve as valuable marker for identifying individuals at elevated ASCVD risk.</summary>
    <dc:date>2025-09-01T00:00:00Z</dc:date>
  </entry>
</feed>

